title: Results of heparin-bonded ePTFE-covered stents for chronic occlusive superficial femoral artery disease.
abstract: OBJECTIVE
  The purpose of this study was to assess the 1-year patency rates of heparin-bonded covered stents in the treatment of chronic occlusive disease of the superficial femoral artery (SFA).
  
  
  METHODS
  All patients treated with a heparin-bonded endograft between April 2009 and October 2010 for chronic occlusive disease of the SFA were prospectively gathered in a database and retrospectively analyzed. Primary, primary-assisted, and secondary patency rates, assessed by ultrasound scanning, were analyzed at 1-year, as were the complication rates and mortality.
  
  
  RESULTS
  A total of 56 limbs were treated with a heparin-bonded covered stent in 53 patients for chronic ischemia Rutherford category 3 (n = 36), 4 (n = 5), 5 (n = 11), and 6 (n = 1). Lesions were classified as TransAtlantic Inter-Society Consensus (TASC)-2-B (n = 9), C (n = 14), and D (n = 33), and the mean treated lesion length was 18.5 ± 7.7 cm. Postoperative complications occurred in 7.5%, including hematoma (n = 1), edema (n = 1), pneumonia (n = 1), and urinary retention (n = 1), and the 30-day mortality rate was 0%. The mean follow-up was 413 ± 208 days. At 1 year, the primary patency was 76%, the primary-assisted patency 82%, and the secondary patency 89%. The limb salvage rate was 100%.
  
  
  CONCLUSIONS
  Heparin-bonded covered stents seem to provide a valid alternative to surgical treatment of long occlusive lesions in the SFA. Randomized trials and long-term data are required before considering the technique as a new standard of care.
authors.affiliation: Department of Surgery, Rijnstate Hospital, Arnhem, The Netherlands.
authors.forename: Mare M A
authors.initials: MM
authors.lastname: Lensvelt
authors.forename: Wilbert M
authors.initials: WM
authors.lastname: Fritschy
authors.forename: Jacques A
authors.initials: JA
authors.lastname: van Oostayen
authors.forename: Suzanne
authors.initials: S
authors.lastname: Holewijn
authors.forename: Clark J
authors.initials: CJ
authors.lastname: Zeebregts
authors.forename: Michel M P J
authors.initials: MM
authors.lastname: Reijnen
mesh_terms: D000368:Aged; D055109:Ankle Brachial Index; D001157:Arterial Occlusive Diseases / Q000000981:diagnostic imaging / Q000601:surgery*; D002908:Chronic Disease; D020099:Coated Materials, Biocompatible; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000473:pathology* / Q000601:surgery*; D006493:Heparin; D006801:Humans; D008297:Male; D016491:Peripheral Vascular Diseases / Q000000981:diagnostic imaging / Q000601:surgery*; D011138:Polytetrafluoroethylene; D011183:Postoperative Complications; D011446:Prospective Studies; D015607:Stents; D016896:Treatment Outcome; D014463:Ultrasonography; D014654:Vascular Patency
chemical_list: D020099:Coated Materials, Biocompatible; D011138:Polytetrafluoroethylene; D006493:Heparin